• Guard Therapeutics

  Participated · Equity · Nov 2022

  Guard Therapeutics develops novel therapies targeting diseases with high unmet medical need, with a lead candidate RMC-035 that has received FDA Fast Track designation. RMC-035 is being developed as a kidney-protective treatment in connection with open heart surgery. The company recently raised 120 million SEK in new capital to support its clinical program. The proceeds will secure completion of the ongoing global phase 2 study (AKITA) and finance selected preparatory phase 3 activities, including CMC development. Leadership says the new financing broadens the investor base and enables initiation of targeted activities toward a subsequent registrational study.

• Arundo Analytics

  Participated · Series A · Jan 2018

  Arundo Analytics builds cloud-based, edge-enabled software to deploy and manage enterprise-scale industrial data science and machine learning. Its platform is purpose-built for deep industrial data science and enables applications such as equipment monitoring and sensor anomaly detection. The company targets operators, OEMs and service companies in asset-heavy sectors that struggle to capitalize on operational data due to legacy assets and harsh operating conditions. Arundo cites a heritage in the maritime industry and says its software lets customers drive business value from operating data in days or weeks rather than months or years. It plans to use the new financing to expand sales and marketing across oil & gas, maritime, mining, chemicals, power and manufacturing, and to grow engineering and data science teams in Houston, Oslo and Palo Alto, with recent hires in Lausanne and London. Financially, Arundo announced an initial closing of a $25 million Series A and has raised over $32.5 million since its 2015 founding.

No current team members are available.